-

Kirby McInerney LLP Reminds Integral Ad Science Holding Corp. (IAS) Investors of Class Action Filing and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors who purchased Integral Ad Science Holding Corp. (“IAS” or the “Company”) (NASDAQ:IAS) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to the securities fraud class action lawsuit against the Company.

[CONTACT FORM]

The lawsuit was filed on behalf of investors who acquired IAS securities from March 2, 2023, through February 27, 2024 (“the Class Period”). Investors have until March 31, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The complaint alleges that defendants, throughout the Class Period, misrepresented and/or failed to disclose that: (1) that IAS was experiencing a new material trend of increased competitive pricing pressures and that, as a result, IAS had been forced to cut prices to compensate for weakening demand and slowing revenue growth; (2) that IAS’s pricing function was no longer ‘favorable’ and IAS could not sustain its pricing and drive price increases; (3) that pricing had become a key differentiator between IAS and its competitor necessary to close major renewals and new deals; and (4) that the risk that competition “could result in increased pricing pressure” or “could put pressure on us to change our prices” had in fact transpired.

[LEARN MORE ABOUT THE CLASS ACTION]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:IAS

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

REMINDER: Atara Biotherapeutics, Inc. Investors With Significant Losses Must Act By May 22, 2026 – Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ:ATRA) investors of the May 22, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors a...

ELV INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Elevance Health, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Elevance Health, Inc. (“Elevance” or the “Company”) (NYSE:ELV) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On March 2, 2026, Elevance disclosed in a filing with the U.S. Securities and Exchange Commission that it “was not...

ALIT INVESTOR REMINDER: Alight, Inc. Investors Have Until May 15, 2026 To Seek Lead Plaintiff Role

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Alight, Inc. (“Alight” or the “Company”) (NYSE:ALIT) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until May 15, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead...
Back to Newsroom